US Patent 10584174 Anti-Dkk-1-anti-RANKL bispecific antibody compounds
Patent 10584174 was granted and assigned to Eli Lilly and Company on March, 2020 by the United States Patent and Trademark Office.
All edits
Edits on 11 Dec, 2023
Golden AI
Edits made to:
Article (+281 characters)
Article
Patent abstract
Bispecific antibody compounds, and methods of using same, are provided which bind and neutralize Dkk-1 and RANKL and which are useful as adjuncts to spinal fusion surgery or as agents for bone healing or treating conditions associated with bone loss or degeneration.
Edits on 27 Apr, 2023
Golden AI
Infobox
Is a
Patent Applicant
Current Assignee
Patent Jurisdiction
Patent Number
105841740
Date of Patent
March 10, 2020
0Patent Application Number
155707560
Date Filed
May 12, 2016
0Patent Citations
Patent Primary Examiner
Edits on 25 Sep, 2022
Golden AI
Infobox
Is a
Patent Applicant
Current Assignee
Patent Jurisdiction
Patent Number
105841740
Date of Patent
March 10, 2020
0Patent Application Number
155707560
Date Filed
May 12, 2016
0Patent Citations
Patent Primary Examiner
Golden AI
Infobox
Patent Citations
Edits on 2 Feb, 2022
Golden AI
Edits made to:
Infobox (+10 properties)
US Patent 10584174 Anti-Dkk-1-anti-RANKL bispecific antibody compounds
Infobox
Is a
Patent applicant
Current assignee
Patent jurisdiction
Patent number
10584174
Date of patent
March 10, 2020
Patent application number
15570756
Date Filed
May 12, 2016
Patent citations
Patent primary examiner
Find more entities like US Patent 10584174 Anti-Dkk-1-anti-RANKL bispecific antibody compounds
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
By using this site, you agree to our Terms of Service.